Drug Pipeline News

Trastuzumab deruxtecan resulted in a statistically significant improvement in progression-free survival and overall survival compared with physician’s choice of chemotherapy in patients with HER2-low unresectable and/or metastatic breast cancer, irrespective of hormone receptor status, meeting the primary and secondary end points of the phase 3 DESTINY-Breast 04 trial.

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

In this exclusive video interview, Michal Elovitz, MD, chief medical advisor at Mirvie, discusses the latest data from the RNA testing platform in predicting preterm birth at the SMFM 42nd Annual Pregnancy Meeting.

Medication can now be used as few as 6 times a year for virologically suppressed adults living with the disease without prior treatments not working or resistance to cabotegravir or rilpivirine.

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

The drug is used to treat bacterial vaginosis and is a generic version of Bausch Health US LLC’s MetroGel-Vaginal.

A phase 2, multicenter study has found relugolix (Myfembree; Myovant Sciences) significantly decreases menstrual blood loss in women with uterine leiomyomas and is mostly well tolerated. Relugolix is a small molecule gonadotropin-releasing hormone (GnRH) receptor antagonist.

Maneesh Jain, CEO and co-founder of Mirvie, a proprietary RNA platform that uses blood samples to predict pregnancy complications such as preeclampsia, sits down with Contemporary OB/GYN to discuss the potential of the test.

Agile Therapeutics, Inc. announced today the U.S. commercial launch of Twirla (levonorgestrel and ethinyl estradiol) transdermal system, a new non-daily, non-invasive contraceptive patch.